
    the decision is based on a change in the benefit risk assessment of this drug for the lupus
    population targeted in this study.
  
['lupus erythematosus, systemic']
['jnj-56022473', 'placebo']

        Inclusion Criteria:

          -  Subject must have a body weight in the range of 40 to 100 kilogram (kg), inclusive,
             and have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m^2),
             inclusive, at screening

          -  Subjects eligible for enrollment in this study must qualify as follows: a) must meet
             Systemic Lupus International Collaborating Clinics (SLICC) criteria for diagnosis of
             lupus and b) must have at least one non-serologic clinical activity defined by the
             Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) within 3 months
             prior to first study agent administration

          -  Have a positive gene signature score during screening, prior to first administration
             of study agent

          -  Subjects using allowed pre-existing lupus treatments, if stable for at least 6 weeks
             prior to the first dose of study medication:

               1. oral corticosteroids equivalent to an average dose up to or equal to (<=) 10
                  milligram (mg) of prednisone/day

               2. use of antimalarials (such as chloroquine or hydroxychloroguine) for at least 8
                  weeks

               3. maximum of 1 non-corticosteroid immunosuppressive drug

        Exclusion Criteria:

          -  Subject with history or suspected occurrence of drug-induced systemic lupus
             erythematosus (SLE)

          -  Subject has unstable lupus nephritis and/ or has active Central nervous system (CNS)
             lupus or history of severe CNS lupus, including but not limited to seizures,
             psychosis, transverse myelitis, CNS vasculitis and optic neuritis

          -  Major surgery prior to, and, if planned, during and shortly after the study is not
             eligible

          -  Subject has or has had an acute illness, including a common cold, within 2 weeks prior
             to the study agent administration or has had a major illness or hospitalization within
             4 months prior to the screening visit

          -  Any other inflammatory diseases that might confound the evaluations of efficacy are
             excluded
      